Matches in SemOpenAlex for { <https://semopenalex.org/work/W2148974931> ?p ?o ?g. }
Showing items 1 to 99 of
99
with 100 items per page.
- W2148974931 abstract "High‐grade gliomas (WHO grade III anaplastic astrocytoma and grade IV glioblastoma multiforme) are the most common primary tumors in the central nervous system in adults and uniformly lethal. The current standard treatment (radiotherapy and temozolomide chemotherapy) has only a modest efficacy and better treatments are urgently needed. Activation of the EGFR/PI3K/Akt/mTor signaling cascade is a common event, especially in de novo glioblastoma (GBM) and, therefore, an attractive target for intervention by inhibitors. However, the blood‐brain barrier (BBB) is an impediment for the delivery of many agents into the brain. Although GBM has the capacity to disrupt the blood‐brain barrier, it is also a very invasive tumor with many tumor cells residing within areas of the brain where the BBB is still intact. Consequently it is important to consider the BBB penetration of novel candidate drugs for treatment of gliomas. We here present a pre‐clinical pharmacokinetic study of Palomid 529, which is a novel small molecule inhibitor of mTor. This agent is attractive because it inhibits both the Torc1 and Torc2 complexes, thereby preventing upstream Akt activation through feedback loops. We have used in vitro transwell assays and found that Palomid 529 has negligible affinities for P‐glycoprotein (Pgp) and Bcrp1, the two most dominant drug transporters that are expressed at the BBB. Subsequent studies in transporter knockout mouse models receiving i.v. P529 as a micronized drug formulation at a high dose (54 mg/kg) or low dose (5.4 mg/kg) confirmed these results and demonstrated that Palomid 529 penetrates the BBB efficiently with brain‐to‐plasma ratios exceeding 1. Only at the lowest dose level a minor effect of Pgp and Bcrp1 was observed. Based on these results we are now executing pre‐clinical testing of Palomid 529 against orthotopic brain tumor models. Citation Information: Mol Cancer Ther 2009;8(12 Suppl):A148." @default.
- W2148974931 created "2016-06-24" @default.
- W2148974931 creator A5034151807 @default.
- W2148974931 creator A5048607320 @default.
- W2148974931 creator A5061723541 @default.
- W2148974931 creator A5062227574 @default.
- W2148974931 creator A5073588166 @default.
- W2148974931 date "2009-12-10" @default.
- W2148974931 modified "2023-10-02" @default.
- W2148974931 title "Abstract A148: Palomid 529, a dual mTor1/2 inhibitor, efficiently penetrates the blood‐brain barrier and may be an attractive agent for treatment of glioblastoma" @default.
- W2148974931 doi "https://doi.org/10.1158/1535-7163.targ-09-a148" @default.
- W2148974931 hasPublicationYear "2009" @default.
- W2148974931 type Work @default.
- W2148974931 sameAs 2148974931 @default.
- W2148974931 citedByCount "1" @default.
- W2148974931 countsByYear W21489749312023 @default.
- W2148974931 crossrefType "proceedings-article" @default.
- W2148974931 hasAuthorship W2148974931A5034151807 @default.
- W2148974931 hasAuthorship W2148974931A5048607320 @default.
- W2148974931 hasAuthorship W2148974931A5061723541 @default.
- W2148974931 hasAuthorship W2148974931A5062227574 @default.
- W2148974931 hasAuthorship W2148974931A5073588166 @default.
- W2148974931 hasConcept C104317684 @default.
- W2148974931 hasConcept C114851261 @default.
- W2148974931 hasConcept C126322002 @default.
- W2148974931 hasConcept C133936738 @default.
- W2148974931 hasConcept C142724271 @default.
- W2148974931 hasConcept C149011108 @default.
- W2148974931 hasConcept C178790620 @default.
- W2148974931 hasConcept C185592680 @default.
- W2148974931 hasConcept C2776194525 @default.
- W2148974931 hasConcept C2777389519 @default.
- W2148974931 hasConcept C2778227246 @default.
- W2148974931 hasConcept C2778402981 @default.
- W2148974931 hasConcept C2778707650 @default.
- W2148974931 hasConcept C2779130545 @default.
- W2148974931 hasConcept C2779820397 @default.
- W2148974931 hasConcept C502942594 @default.
- W2148974931 hasConcept C529278444 @default.
- W2148974931 hasConcept C55493867 @default.
- W2148974931 hasConcept C62478195 @default.
- W2148974931 hasConcept C71924100 @default.
- W2148974931 hasConcept C75217442 @default.
- W2148974931 hasConcept C86554907 @default.
- W2148974931 hasConcept C86803240 @default.
- W2148974931 hasConcept C89423630 @default.
- W2148974931 hasConcept C98274493 @default.
- W2148974931 hasConceptScore W2148974931C104317684 @default.
- W2148974931 hasConceptScore W2148974931C114851261 @default.
- W2148974931 hasConceptScore W2148974931C126322002 @default.
- W2148974931 hasConceptScore W2148974931C133936738 @default.
- W2148974931 hasConceptScore W2148974931C142724271 @default.
- W2148974931 hasConceptScore W2148974931C149011108 @default.
- W2148974931 hasConceptScore W2148974931C178790620 @default.
- W2148974931 hasConceptScore W2148974931C185592680 @default.
- W2148974931 hasConceptScore W2148974931C2776194525 @default.
- W2148974931 hasConceptScore W2148974931C2777389519 @default.
- W2148974931 hasConceptScore W2148974931C2778227246 @default.
- W2148974931 hasConceptScore W2148974931C2778402981 @default.
- W2148974931 hasConceptScore W2148974931C2778707650 @default.
- W2148974931 hasConceptScore W2148974931C2779130545 @default.
- W2148974931 hasConceptScore W2148974931C2779820397 @default.
- W2148974931 hasConceptScore W2148974931C502942594 @default.
- W2148974931 hasConceptScore W2148974931C529278444 @default.
- W2148974931 hasConceptScore W2148974931C55493867 @default.
- W2148974931 hasConceptScore W2148974931C62478195 @default.
- W2148974931 hasConceptScore W2148974931C71924100 @default.
- W2148974931 hasConceptScore W2148974931C75217442 @default.
- W2148974931 hasConceptScore W2148974931C86554907 @default.
- W2148974931 hasConceptScore W2148974931C86803240 @default.
- W2148974931 hasConceptScore W2148974931C89423630 @default.
- W2148974931 hasConceptScore W2148974931C98274493 @default.
- W2148974931 hasLocation W21489749311 @default.
- W2148974931 hasOpenAccess W2148974931 @default.
- W2148974931 hasPrimaryLocation W21489749311 @default.
- W2148974931 hasRelatedWork W178870454 @default.
- W2148974931 hasRelatedWork W2056857399 @default.
- W2148974931 hasRelatedWork W2058481731 @default.
- W2148974931 hasRelatedWork W2083820705 @default.
- W2148974931 hasRelatedWork W2325600619 @default.
- W2148974931 hasRelatedWork W2336707673 @default.
- W2148974931 hasRelatedWork W2340212301 @default.
- W2148974931 hasRelatedWork W2406263010 @default.
- W2148974931 hasRelatedWork W2466581939 @default.
- W2148974931 hasRelatedWork W2548516618 @default.
- W2148974931 hasRelatedWork W2590048118 @default.
- W2148974931 hasRelatedWork W2734398030 @default.
- W2148974931 hasRelatedWork W2790645070 @default.
- W2148974931 hasRelatedWork W2802016612 @default.
- W2148974931 hasRelatedWork W2809134358 @default.
- W2148974931 hasRelatedWork W2833068522 @default.
- W2148974931 hasRelatedWork W2980534481 @default.
- W2148974931 hasRelatedWork W2998975075 @default.
- W2148974931 hasRelatedWork W3013258896 @default.
- W2148974931 hasRelatedWork W3017151862 @default.
- W2148974931 isParatext "false" @default.
- W2148974931 isRetracted "false" @default.
- W2148974931 magId "2148974931" @default.
- W2148974931 workType "article" @default.